Role of allopurinol and rofecoxib in agranulocytosis and acute tubular necrosis;Implicación de alopurinol y rofecoxib en agranulocitosis y necrosis tubular aguda

Farmacia Hospitalaria

Volumn 27, Issue 5, 2003, Pages 317-322

  Real Panisello, Marina ^a   Vila Clerigues N ^a   Garcia Reina L ^a   Luaces Vidal, F ^a   Gonzalez Ponce C M ^a   Diaz Carrasco M S ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Acute tubular necrosis; Adverse event; Agranulocytosis; Allopurinol; Rofecoxib

Indexed keywords

ALLOPURINOL; ROFECOXIB;

ACUTE KIDNEY TUBULE NECROSIS; AGED; AGRANULOCYTOSIS; ALGORITHM; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; KIDNEY BIOPSY; MALE; NEUTROPENIA; THROMBOCYTOPENIA;

AGED; AGRANULOCYTOSIS; ALLOPURINOL; CYCLOOXYGENASE INHIBITORS; ENZYME INHIBITORS; HUMANS; KIDNEY TUBULAR NECROSIS, ACUTE; LACTONES; MALE; SULFONES;

EID: 0142075232     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Drugdex editorial staff. Drugdex Information System Micromedex. Inc. Denver Drug evaluation monograf of rofecoxib and allopurinol, 2002.
2. Flórez J. Farmacología humana, 3° ed. Masson, 1998.
3. Stewart Cameron J, Simmond H Anne. Use and abuse of allopurinoll. British Medical Journal 1987; 294: 1504-5.
4. Vázquez Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60: 981-3.
5. Lorenzo Sellares V. Manual de nefrología clínica, diálisis y trasplante renal. Harcourt Brace, 1998.
6. Farreras, Rozmán. Medicina Interna. 13° ed.
7. Stubanus M, Riegger Günter AJ, Kammed MCm, Fischereder M, Kramer BK. Renal side effects of cyclo-oxygenasa-type 2 inhibitor use. The Lancet 2000; 355: 753-4.
8. Ahmad R, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25 (7): 537-44.
9. Chiolero A, Wurzner G, Burnier M. Les inhibiteurs selectifs de la cyclooxygenase de type 2: moins d'effects renaux que les anti-inflammatoires non steroidiens classiques? Nephrologie 2000; 21: 425-30.
10. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function focus on cylooxygenase-2 selective inhibition. Am J Med 1999; 107: 655-705.
11. Deray G. Tolerance renales des inhibiteurs specifiques de la cyclooxigenase de type 2. Presse Med 2001; 30: 1507-12.
12. Whelton A, Hamilton CW. Nonsteroidal anti-infalmatory Drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588-98.
13. Rocha JL, Fernández Alonso J. Acute tubulointersticial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001; 357: 1946-7.
14. Woywodt A, Schwarz A, Mengel M, Haller H, Zeidler H, Kohler L. Nephrotoxicity of selective COX-2 inhibitors. J Rheumatol 2001; 28: 2133-5.
15. Woy G, Porth J, Stahl RAK. Acute renal failure associated with rofecoxib. Ann Intern Med 2000; 133 (5): 394.
16. Anon. Allopurinol ADRS in Sweden include fatal aplastic anemia. Reactions 2001; 849: 4.
17. Shinohara, et al. Aplastic anemia caused by allopurinol in renal insuficiency (letter). Am J Hematol 1990; 35 (1): 68.
18. McInnes, et al. Acute adverse reaction attributed to allopurinol in hospitalized patients. Ann Rheum Dis 1981; 40: 245-9.
19. Rosenbloon D, Gilbert R. Reversible flu-like sindrome, leukopenia and thombocytopenia induced by allopurinol. Drug Intell Clin Pharm 1981; 15: 286-7.
20. Wilkinson DG. Allopurinol and agranulocytosis (letter). Lancet 1977; 2: 1282-3.
21. Vicent PC. Drug induced aplastic anaemia and agranulocytosis. Incidence and mechanisms. Drugs 1986; 31: 52-63.
22. Roeser HP. Drug-bone marrow interactions. The Medical Journal of Australia 1987; 146: 145-8.
23. Rosen Saul. Agranulocytosis. JAMA 1994; 271: 935-8.
24. Greenberg MS, Zambrano SS. Aplastic agranulocytosis after allopurinol therapy. Arthritis Rheum 1972; 15: 413-6.
25. Wikinson DG. Allopurinol and agranulocytosis. Lancet 1977; 2 (8051): 1282-3.
26. Allopurinol and agranulocytosis. The Medical Journal of Australia 1980; 22: 283-4.
27. Lee EJ, Kueh YK. Allopurinol induced skin reactions and agranulocytosis. Singapure Med J 1982; 23: 178-80.
28. Schar B, Meier C, Affolter H. Drug induced (probably allopurinol) agranulocytosis. Case report and discussion. Schweiz Med Wochenschr 1994; 124: 545-9.
29. Paller MS. Drug induced nephropathies. Med Clin North Am 1990; 74: 909-17.
30. González V, Reyes E, Kershenovich J, Orozco-Topete RL. Síndrome de hipersensibilidad per alopurinol. Un caso de necrosis hepática masiva. Rev Invest Clin 1995; 47 (5): 409-13.
31. Morel D, Guez S, Merville P, Deminiere C, Tamisier JM, Potaux L. Recurent renal failure associated with hypersensitivitty to allopurinol. Nephrol Dial Transplant 1999; 14 (3): 780-1.